Skip to content
value.today

Elixir Pharmaceuticals, Inc.

Formerly ELIXIR PHARMACEUTICALS INC

Total raised
$12 M
1 round on record
Latest round
$12 M
May 2009
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Elixir Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2009$12 MNo. 1$10 to $50 million

Elixir Pharmaceuticals, Inc.: Raise no. 1, May 2009

Investors in this round

36 investors had bought by the notice of May 28, 2009: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $25 M offered; $13 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Karen Roberts · Executive Officer
  • Paul M. Martha · Executive Officer, Director
  • Peter S. DiStefano · Executive Officer
  • Robert Kriebel · Executive Officer
  • Ansbert Gadicke · Director
  • Dion Madsen · Director
  • Kenneth Greenberg · Director
  • Vaughn M. Kailian · Director
  • Vernon Cassin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Karen Roberts, Treasurer. Source: SEC Form D, newest notice filed May 28, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Elixir Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2009).

    SEC Form D · May 2009

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2009

That is all the official record says: Elixir Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Elixir Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elixir Pharmaceuticals, Inc.
NameRoleNamed in
Karen RobertsExecutive officerMay 2009
Paul M. MarthaExecutive officerMay 2009
Peter S. DiStefanoExecutive officerMay 2009
Robert KriebelExecutive officerMay 2009
Ansbert GadickeDirectorMay 2009
Dion MadsenDirectorMay 2009
Kenneth GreenbergDirectorMay 2009
Paul M. MarthaDirectorMay 2009
Vaughn M. KailianDirectorMay 2009
Vernon CassinDirectorMay 2009